Reported Earlier, Teknova And Pluristyx Announce Strategic Collaboration To Commercialize PluriFreeze, Streamlining Cell Therapy Development

-1.95%

Alpha Teknova, Inc.

TKNO

5.54

-1.95%

Alpha Teknova, Inc. and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx's PluriFreeze™ product line, a cryopreservative and cell wash media system intended for use by customers who are developing next generation allogeneic cell therapies. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading and safety-switch enabled iPSCs, and other innovative technologies designed to shorten the development lifecycle of tomorrow's cell therapies.

Through their developmen

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.